Introduction
============

Cancer is a term that refers to the rapid growth and division of abnormal cells in a part of the body.[@b1-ijn-13-2321] These cells promote alterations in primary tissue and have the ability to invade different parts of the body and spread to other organs[@b2-ijn-13-2321] originating metastasis, which constitutes a challenge in cancer treatment.[@b3-ijn-13-2321] There are \>100 types of cancers, and different risk factors contribute to the development of cancers in different sites.[@b4-ijn-13-2321] Cancer is the second cause of death and its main risk factor is aging. This fact is alarming, since a double of the population older than 65 years is expected to be affected in the next 20 years, increasing from 616 million to 1,157 billion worldwide.[@b5-ijn-13-2321]

The most incident type of cancer is the non-melanoma skin for both sexes, followed by prostate cancer in men and breast cancer in women, which affects women the most worldwide.[@b1-ijn-13-2321] Breast tumors are categorized into three main classes: those in which cells have estrogen receptor (ER+) or progesterone receptor (PR+), those in which cells have human epidermal growth factor receptor-2 (HER-2+) with or without ER+, and the triple negative breast cancer (TNBC) defined by the absence of these receptors.[@b6-ijn-13-2321],[@b7-ijn-13-2321]

TNBC affects 9%--16% of the population worldwide, has a poor prognosis related to cure and survival, has high relapse rates, and has no targeted therapies.[@b8-ijn-13-2321] Basically, breast cancer treatment constitutes surgery, chemotherapy, and radiotherapy.[@b9-ijn-13-2321] There is an urgent need for chemotherapeutics that act selectively to inhibit neoplastic cell growth, leaving the non-tumor cells intact.[@b10-ijn-13-2321] However, the majority of the drugs used in chemotherapy are mutagenic and cause damage to DNA from the tumor and non-tumor cells, leading to the death of rapidly dividing cells, which is associated with the collateral effects observed in patients.[@b11-ijn-13-2321]

Aiming to improve the efficacy to decrease toxicity and increase the bioavailability of chemotherapy medication, nanotechnology has emerged as an important option.[@b12-ijn-13-2321],[@b13-ijn-13-2321] Nanoparticles accumulate preferentially in the tumors due to the presence of well defined characteristics in tumors mass, such as the defective vasculature and poor lymphatic drainage, resulting in an increase in permeation and retention effect.[@b14-ijn-13-2321],[@b15-ijn-13-2321] For antitumor treatment, nanoparticles may serve as carriers of compounds with higher selectivity for primary tumor and metastases, reducing the drug resistance and side effects.[@b16-ijn-13-2321] In TNBC, gold nanoparticles conjugated with folic acid have shown significantly higher cell entry rates in both in vitro and in vivo models, indicating that folate receptors can be used as targeted therapies for TNBC.[@b17-ijn-13-2321] This pattern was also observed with fructose-coated nanoparticles showing high selectivity (100-fold) for breast cancer cells compared to normal cells.[@b18-ijn-13-2321]--[@b20-ijn-13-2321]

This review aims to provide an update of the scientific production related to nanoparticles for breast cancer treatment, mainly for the triple negative subtype, during the period between 2012 and 2017.

Materials and methods
=====================

Literature search was performed in August 2017 in Scopus database, using the keywords (nanotechnology OR nanomedicine OR nanoparticle OR drug carrier) AND (triple negative breast cancer OR TNBC OR breast cancer), and was confined to articles published in journals related to Biotechnology, Pharmacology, Toxicology and Pharmaceutics, and Medicine areas, published in the period ranging from 2012 to 2017, and written in English language.

The results regarding authors who are publishing in the field were analyzed through tools in Scopus database. Impact factor (IF) of the journals was analyzed using InCites Journal Citation Reports from Thomson Reuters. VOSviewer version 1.6.0 software (Leiden University, Leiden, the Netherlands) was used to analyze the relationship between the most cited references and the most productive authors to generate the map and clusters visualization. STATA software and Microsoft Excel 2013 were used to calculate the cumulative volume and to predict paper trends using polynomial multiple regression models. GraphPad Prism 5 and RSudio 1.1.383 were used to create graphics.

Results
=======

General information
-------------------

The initial number of identified studies using the keyword combination was 4,676. After exclusions, the final number was 1,932, as demonstrated in the flow chart depicted in [Figure 1](#f1-ijn-13-2321){ref-type="fig"}.

In the period ranging from 2012 to 2017, 1,932 papers were published by 7,666 authors on the theme in 425 journals using 14,614 keywords ([Table 1](#t1-ijn-13-2321){ref-type="table"}). There was a growth in the annual number of papers, from 200 in 2012 to 1,757 in 2016, with a projection of 2,256 for 2017 and 2,798 for 2018. In this period, the increase in the number of publications can be represented by the polynomial regression model: y=21.93 x^2^−87,939.19x+88,163,841.66, with y being the year and x being the cumulative volume of papers ([Figure 2](#f2-ijn-13-2321){ref-type="fig"}).

For the prediction model, functional specification, linear, logarithmic, polynomial, and exponential equations were tested. Hence, the choice of a second-order polynomial model for [Figures 2](#f2-ijn-13-2321){ref-type="fig"} and [3A and B](#f3-ijn-13-2321){ref-type="fig"} was based on the maximization of the *R*^2^ goodness-of-fit coefficient of the available historical data, from 2012 to 2017, which served as the basis for choosing the model with the highest *R*^2^.

Countries
---------

The most productive country in terms of publication, using the keywords already mentioned, was the USA with 548 papers, representing 28.36% of total publications ([Figure 3A](#f3-ijn-13-2321){ref-type="fig"}). After this, China and India occupied second and third positions, respectively, with 494 (25.56%; [Figure 3B](#f3-ijn-13-2321){ref-type="fig"}) and 257 (13.30%) papers ([Figure 3C](#f3-ijn-13-2321){ref-type="fig"}). The choice of the functional specification for [Figure 3A](#f3-ijn-13-2321){ref-type="fig"} followed the same *R*^2^ maximization logic; consequently, for the USA, the best specification was linear. This displays that India, China, and the USA show a growing trend in publications. However, the USA has a steady rate, while India and China are growing at increasing rates; thus, the expectation is that by 2018, China (which has the steepest growth rate) will exceed the USA in the number of publications. The top 10 countries that published more articles from 2012 to 2017 are shown in [Figure 3D](#f3-ijn-13-2321){ref-type="fig"}.

The papers were cited 26,450 times. The citation frequency was 13.69 times per paper. Singapore was the country that had the highest average of article citations (27 times). The number of citations of all papers from the USA was 7,304, comprising 27.61% of the total citations. China was in the second position with 7,126. The top 10 most cited countries are shown in [Figure 4](#f4-ijn-13-2321){ref-type="fig"}.

Institutes
----------

The institute with the largest number of publications and citations in the area of nanotechnology and TNBC during the period was the Chinese Academy of Sciences, with 99 papers and 1,832 citations, comprising 5.12% of the total literature, and being the most cited institute. There are five other Chinese institutes in top 10 of the most cited publications and 2 are from Iran ([Table 2](#t2-ijn-13-2321){ref-type="table"}). The USA was the country that was the most cited; however, the US institutes do not appear among the top 10 that published the most in the field. The M.D. Anderson Cancer Center from the University of Texas with 25 publications and 693 citations and the Harvard Medical School with 18 publications and 616 citations were the American institutes that published the most in the area.

Journals
--------

The top 10 journals published 625 papers in the area of TNBC and nanotechnology, comprising 32.34% of the total. *Biomaterials* (IF 8.402; 2016) had the largest number of publications with 120 papers and was the most cited journal with 4,180 citations, followed by *International Journal of Nanomedicine* (IF 4.300; 2016) with 113 papers and 1,332 citations and *International Journal of Pharmaceutics* (IF 3.649; 2016) with 70 documents and 970 citations. The top 10 journals publishing in the area are shown in [Table 3](#t3-ijn-13-2321){ref-type="table"}.

Authors, patents, and clinical trials
-------------------------------------

The top 10 most productive authors had a total of 160 papers, contributing to 8.3% of all publications in the field. In the period ranging from 2012 to 2017, "Li, Yaping" from Shanghai Institute of Materia Medica (China) produced most papers in the area, with 23 articles. His most cited paper is entitled "Co-delivery of doxorubicin and RNA using pH-sensitive poly (β-amino ester) nanoparticles for reversal of multidrug resistance of breast cancer" (2014) with 56 citations. "Atyabi, F" and "Yu, Hainjun" published 18 articles each. Furthermore, during the same period, \>9,000 patents were filed; thus, the patents filed by the 10 authors who published the most were searched. Of these, four authors filed patents. "Ferrari, Mauro" was the most productive with 10 patents. The top 10 authors in this area are shown in [Table 4](#t4-ijn-13-2321){ref-type="table"}, and a list of their patents is shown in [Table 5](#t5-ijn-13-2321){ref-type="table"}.

We also performed a search on the current scenario of clinical trials in the area of TNBC and nanotechnology using the same combination of keywords described in the section "Materials and methods". The search resulted in 12 studies ([Table 6](#t6-ijn-13-2321){ref-type="table"}). One study was excluded since it did not involve nanotechnology. Of the remaining 11 studies, 2 have their results reported. Two of them were related to the use of Abraxane^®^ in a combined regimen with carboplatin or carboplatin and bevacizumab. Abraxane is a nanoparticle containing albumin-bound paclitaxel and bevacizumab in an anti-vascular endothelial growth factor antibody.

The results regarding the safety and tolerability for the clinical trial using Abraxane and carboplatin were not presented, according to the report provided, due to insufficient accrual for the study. However, 60% of patients (6/10) presented serious adverse effects, such as anemia, alterations in neutrophil count, gastrointestinal disorders, and allergic reactions, after treatment. All the patients (10/10) had other adverse effects such as nausea, edema, and pain. This study was terminated.

The study using Abraxane with carboplatin and bevacizumab involved 41 women with TNBC in stage IV or inoperable stage III. Results of 39 patients were provided. Of them, 18% had complete response, 69% had partial response, 8% presented stable disease, and only 5% had progressive disease. The duration of progression-free disease was 15 months; however, 53.66% and 100% of the participants had serious adverse effects and other adverse effects, respectively.

Overall, the scenario on TNBC and nanotechnology is not greatly encouraging currently. As in traditional chemotherapy, adverse effects of the regimens seem to be the main cause of concern. Notwithstanding, further research and the introduction of different nanosystems are pivotal for the improvement of therapeutic options for TNBC.

Articles
--------

The top 10 most cited articles had 2,224 citations, representing 8.4% of the total citations. The paper entitled "Preclinical development and clinical translation of PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile" (2012) published in *Science Translational Medicine* by HrKach J et al was the most cited, with 445 citations. The top 10 most cited articles are shown in [Table 7](#t7-ijn-13-2321){ref-type="table"}.

Hotspots
--------

Keywords of 1,932 articles were analyzed in VOSviewer. Of 14,614 keywords, 145 were used \>85 times in titles and abstracts of all papers. Keywords were classified into four clusters formed in the software VOSviewer: "Drugs", "Animal Models", "Human cell lines", and "Properties". In the cluster "Drugs", the most used keywords were "breast cancer" (1,133 times), "drug delivery system" (666 times), and "antineoplasic agent" (544 times).

In the cluster "Animal Models", the most used keywords were "unclassified drug" (685 times), "in vitro study" (584 times), and "particle size" (551 times). In the cluster "Human cell lines", the more frequently used keywords were "human" (1,481 times), "humans" (1,340 times), and "chemistry" (855 times). In the cluster "Properties", the most common keywords were "female" (1,023 times), "nonhuman" (802 times), and "animals" (793 times). Keywords and association lines are shown in [Figure 5](#f5-ijn-13-2321){ref-type="fig"} and listed in [Table S1](#SD1-ijn-13-2321){ref-type="supplementary-material"}.

Several drugs are used in TNBC treatment, and results of clinical studies demonstrated that TNBC patients have different responses to them.[@b47-ijn-13-2321] However, the chemotherapeutic drug widely reported in nanomedicine for the treatment of TNBC was "doxorubicin" (395 times), and the most common carrier nanosystem was "liposome/liposomes" (279 times). Accordingly, during the past few years, various nanomaterials have been developed for the detection and treatment of breast cancer. These nanoparticles are made up of a variety of materials including lipids, polymers, silica, protein/peptides, oligonucleotides, and metals such as gold, silver, and iron.[@b48-ijn-13-2321] We found in this review that the main materials used in the formulations were "macrogol" (191 times), "macrogol derivate" (177 times), and "polyethylene glycols" (265 times).

VOSviewer applied colors to keywords based on the year that they appeared in the literature. Keywords in red appeared early, followed by yellow and green colors, while keywords in blue appeared later. The average year of cluster appearance was close to each other. The cluster "Drugs" had the more recently used keyword "antineoplasic agent" (544 times cited, year of appearance 2014). The cluster "Animal models" had "Breast cancer cell lines" (231 times cited, 2015), the cluster "Human cell lines" had "MCF-7 cell lines" (165 times cited, 2016), and the cluster "Properties" had "Bagg albino mouse" (193 times cited, 2015) as the more recently used keywords ([Figure 6](#f6-ijn-13-2321){ref-type="fig"}). The density map shows the citation concentration areas for keywords ([Figure 7](#f7-ijn-13-2321){ref-type="fig"}).

Conclusion
==========

Nanotechnology cancer field has the potential for improving therapeutic efficacy, creating methods for detection, and targeting different cancer stages. Development of various nanomaterials and nanotechnology had allowed the improvement of cancer biomarkers area with high precision and sensibility that was not the case some years ago. In this study, the global scientific production from the period ranging from 2012 to 2017 related to the nanotechnology applied to TNBC research was analyzed quantitatively and qualitatively. Results showed an increase in the cumulative volume of papers worldwide and a tendency to continue growing in terms of publication numbers. Research has focused on the search for drug carrier systems for the treatment of breast cancer in in vitro studies using the MCF-7 cell line and animal models, specifically Bagg albino mouse. Thus, through the study of the quantitative aspects of the production and dissemination of the knowledge generated in the time interval observed through bibliometric analysis, it was possible to trace the research profiles of different countries, centers, and researchers, offering an important analysis of the scientific production, behavior, and development in this field of research.

Supplementary material
======================

###### 

List of keywords generated by VOSviewer

  Id                                   Cluster   Links   Total link strength   Ocurrences   Avg. pub. year
  ------------------------------------ --------- ------- --------------------- ------------ ----------------
  Antibiotics, antineoplasic           1         142     2,748                 91           2014.32
  Antineoplasic agent                  1         145     15,216                544          2014.86
  Antineoplastic agents                1         145     12,789                466          2014.52
  Antineoplastic agents, phytogenic    1         144     3,049                 110          2014.37
  Breast cancer                        1         145     25,473                1,133        2014.20
  Cancer                               1         145     2,299                 111          2014.31
  Cancer chemotherapy                  1         145     3,622                 135          2014.11
  Cancer therapy                       1         145     3,606                 150          2014.02
  Chemistry, pharmaceutical            1         140     2,597                 89           2014.53
  Chemotherapy                         1         145     3,395                 132          2014.67
  Docetaxel                            1         142     3,174                 128          2014.39
  Doxorubicin                          1         145     10,337                395          2014.38
  Drug carrier                         1         145     12,086                427          2014.87
  Drug carriers                        1         145     13,199                478          2014.49
  Drug delivery                        1         145     5,533                 226          2014.32
  Drug delivery system                 1         145     17,825                666          2014.43
  Drug delivery systems                1         145     8,691                 318          2014.51
  Drug efficacy                        1         145     8,873                 299          2014.26
  Drug formulation                     1         145     6,652                 237          2014.35
  Drug resistance                      1         145     2,946                 93           2014.90
  Drug resistance, neoplasm            1         145     3,199                 110          2014.90
  Drug safety                          1         137     2,056                 85           2014.24
  Drug targeting                       1         145     3,707                 137          2014.07
  Encapsulation                        1         142     2,966                 104          2014.22
  Epidermal growth receptor 2          1         145     2,759                 129          2014.37
  Liposome                             1         145     3,933                 165          2014.10
  Liposomes                            1         144     2,916                 114          2014.18
  Macrogol                             1         145     5,495                 191          2014.18
  Macrogol derivate                    1         144     5,737                 177          2015.06
  Micelle                              1         145     4,475                 149          2014.53
  Micelles                             1         144     4,104                 137          2014.53
  Molecularly targeted therapy         1         145     2,453                 86           2014.37
  Multigrud resistance                 1         144     2,708                 93           2014.69
  Nanocarrier                          1         145     5,136                 179          2014.50
  Nanomedicine                         1         145     4,366                 179          2014.36
  Nanotechnology                       1         145     3,660                 200          2014.15
  Neoplasms                            1         145     4,503                 198          2014.15
  Paclitaxel                           1         145     6,411                 277          2014.26
  Polyethylene glycols                 1         145     7,772                 265          2014.51
  Polymer                              1         145     4,412                 163          2014.44
  Polymers                             1         145     4,078                 149          2014.62
  Antineoplastic activity              2         145     12,103                411          2014.35
  Biocompatibility                     2         145     3,250                 129          2014.44
  Breast cancer cell line              2         144     6,465                 231          2015.23
  Cancer cell                          2         145     6,297                 267          2013.88
  Cancer cell culture                  2         143     3,361                 150          2013.12
  Cell strain MCF-7                    2         141     1,972                 90           2012.83
  Cell survival                        2         145     9,525                 352          2014.43
  Cell viability                       2         145     7,251                 267          2014.50
  Chitosan                             2         144     2,019                 91           2014.87
  Concentration response               2         145     2,310                 86           2014.05
  Confocal microscopy                  2         144     2,658                 99           2014.35
  Cytotoxicity                         2         145     10,253                406          2014.37
  Drug conjugation                     2         145     3,059                 103          2014.53
  Drug cytotoxicity                    2         145     5,914                 204          2014.47
  Drug release                         2         145     9,809                 338          2014.57
  Drug stability                       2         145     3,688                 135          2014.22
  Drug synthesis                       2         145     3,459                 132          2014.37
  Drug uptake                          2         145     3,290                 109          2014.45
  Endocytosis                          2         145     3,664                 125          2014.46
  Flow cytometry                       2         145     4,128                 158          2914.37
  Fluorescence microscopy              2         145     2,217                 89           2014.13
  Human cell                           2         145     20,170                787          2014.32
  Hydrogen ion concentration           2         145     2,670                 89           2014.37
  IC~50~                               2         143     3,263                 103          2015.41
  In vitro study                       2         145     16,554                584          2014.39
  Infrared spectroscopy                2         143     2,917                 122          2014.70
  Internalization                      2         145     3,244                 112          2014.53
  Nanoencapsulation                    2         145     5,072                 175          2014.21
  Particle size                        2         145     14,569                551          2014.48
  pH                                   2         145     4,373                 154          2014.63
  Physical chemistry                   2         145     2,814                 103          2014.48
  Polyglactin                          2         145     2,349                 87           2014.11
  Scanning electron microscopy         2         144     2,429                 111          2014.59
  Surface property                     2         145     2,998                 113          2014.47
  Synthesis                            2         145     3,766                 138          2014.72
  Transmission electron microscopy     2         145     5,382                 227          2014.34
  Unclassified drug                    2         145     16,929                685          2014.13
  Zeta potential                       2         145     6,990                 253          2014.44
  Apoptosis                            3         145     9,513                 354          2014.65
  Breast cancer cells                  3         145     2,200                 105          2014.30
  Breast neoplasms                     3         145     18,161                729          2014.37
  Breast tumor                         3         145     4,316                 182          2014.31
  Cell culture                         3         145     3,973                 169          2014.63
  Cell death                           3         145     5,057                 193          2014.63
  Cell line, tumor                     3         145     21,152                814          2014.33
  Cell proliferation                   3         145     6,910                 263          2014.48
  Cells                                3         145     5,212                 226          2914.90
  Chemistry                            3         145     22,331                855          2015.02
  Cytology                             3         145     4,356                 187          2015.14
  Diseases                             3         145     9,406                 400          2014.87
  Dose response                        3         145     2,356                 87           2014.91
  Drug effects                         3         145     15,154                527          2015.11
  Gene expression                      3         142     2,240                 96           2014.54
  Genetics                             3         145     4,557                 178          2014.98
  Gold                                 3         143     3,108                 161          2014.73
  Gold nanoparticle                    3         144     2,840                 148          2014.28
  Human                                3         145     33,652                1,481        2014.47
  Humans                               3         145     31,754                1,340        2014.39
  MCF-7 cell line                      3         145     8,507                 308          2014.82
  MCF-7 cell lines                     3         143     4,219                 165          2016.04
  MCF-7 cells                          3         145     10,907                419          2014.75
  Metabolism                           3         145     13,700                530          2014.99
  Metal nanoparticle                   3         144     2,822                 146          2014.90
  Metal nanoparticles                  3         143     3,623                 191          2014.61
  Nanoparticle                         3         145     20,739                856          2014.54
  Nanoparticles                        3         145     21,557                918          2014.55
  Pathology                            3         145     12,505                474          2014.92
  Procedures                           3         145     9,188                 368          2015.16
  Protein expression                   3         145     5,090                 200          2014.33
  RNA, small interfering               3         143     2,303                 86           2014.43
  Small interfering RNA                3         145     2,952                 120          2014.33
  Tumor cell line                      3         145     16,200                584          2014.95
  Ultrastructure                       3         144     3,356                 129          2015.16
  Animal                               4         145     16,923                563          2014.90
  Animal cell                          4         145     7,522                 262          2014.27
  Animal experimente                   4         145     17,049                571          2014.31
  Animal model                         4         145     15,890                524          2014.33
  Animal tissue                        4         145     8,724                 293          2014.27
  Animals                              4         145     22,161                793          2014.29
  Bagg albino mouse                    4         145     6,713                 193          2015.00
  Cancer inhibition                    4         145     7,263                 231          2014.35
  Drug distribuition                   4         145     5,077                 157          2014.28
  Drug screening                       4         145     5,716                 180          2014.83
  Female                               4         145     25,711                1,023        2014.41
  In vivo study                        4         145     11,108                360          2014.31
  Magnetic resonance imaging           4         142     2,176                 87           
  Magnetite nanoparticle               4         144     2,027                 90           2014.50
  Magnetite nanoparticles              4         142     2,119                 95           2014.35
  Male                                 4         145     4,262                 151          2014.26
  Mice                                 4         145     14,860                517          2014.18
  Mice, inbred balb c                  4         145     8,385                 256          2014.44
  Mice, nude                           4         145     6,470                 194          2014.43
  Mouse                                4         145     19,679                679          2014.42
  Nonhuman                             4         145     21,738                802          2014.20
  Nuclear magnetic resonance imaging   4         144     2,582                 113          
  Nude mouse                           4         145     5,420                 149          2014.97
  Rat                                  4         145     3,456                 124          2014.43
  Rats                                 4         143     2,374                 91           2014.24
  Tissue distribuition                 4         145     3,387                 114          2014.39
  Treatment outcome                    4         144     2,351                 91           2014.37
  Tumor growth                         4         145     2,848                 93           2014.22
  Tumor volume                         4         145     4,774                 153          2014.52
  Tumor xenograft                      4         145     4,757                 154          2014.24
  Tumors                               4         145     5,707                 218          2014.76
  Xenograft model antitumor assays     4         145     4,978                 150          2014.41

We acknowledge Camila Umbelino Carvalho e Fernando Vieira da Silva for helping us in programming language and performing graphs in software RSudio 1.1.383. This work was supported by São Paulo Research Foundation (FAPESP grants \#2017/19504-0 and 2018/06003-5).

**Author contributions**

All three authors have made substantial contributions to the acquisition, analysis and interpretation of the data in this study. All authors also critically revised the manuscript. The authors agree to be accountable for all aspects of the work.

**Disclosure**

The authors report no conflicts of interest in this work.

![Flow chart of studies used in the analysis.\
**Notes:** \*Document type includes only the articles published in journals. Conference papers, short surveys, editorials, notes, letters, book chapters, and articles in press were excluded. Source type includes only journals. Conference proceedings, book series, and books were excluded from the results.](ijn-13-2321Fig1){#f1-ijn-13-2321}

![Cumulative volume of articles related to nanotechnology and triple negative breast cancer: global trends for 2030.](ijn-13-2321Fig2){#f2-ijn-13-2321}

![Prediction of the number of publications in the field of nanotechnology and triple negative breast cancer expected until 2030 from (**A**) India, (**B**) China, and (**C**) the USA. (**D**) Quantity of publications related to nanotechnology and triple negative breast cancer by country during the period 2012--2017.](ijn-13-2321Fig3){#f3-ijn-13-2321}

![Total and average article citations per country of papers in the area of nanotechnology and triple negative breast cancer during the period 2012--2017.](ijn-13-2321Fig4){#f4-ijn-13-2321}

![Association line of keywords from papers in the area of nanotechnology and triple negative breast cancer.](ijn-13-2321Fig5){#f5-ijn-13-2321}

![Average year map of keywords.](ijn-13-2321Fig6){#f6-ijn-13-2321}

![Density map of keywords.](ijn-13-2321Fig7){#f7-ijn-13-2321}

###### 

General information on articles related to nanotechnology and triple negative breast cancer published in the period from 2012 to 2017

  ---------------------- -------
  Articles               1,932
  Articles per author    0.252
  Author per article     3.97
  Coauthor per article   6.8
  Sources (journals)     425
  Keywords               3,966
  Authors                7,666
  ---------------------- -------

###### 

Main affiliations of authors publishing in the area of nanotechnology and triple negative breast cancer

  Institute                                                 Documents   Citations
  --------------------------------------------------------- ----------- -----------
  Chinese Academy of Sciences                               99          1,832
  Tehran University of Medical Sciences                     56          468
  Ministry of Education China                               43          460
  Sichuan University                                        38          923
  Tabriz University of Medical Sciences                     36          256
  University of Toronto                                     32          131
  Perking University                                        29          513
  National University of Singapore                          28          786
  Shenyang Pharmaceutical University                        27          427
  National Center for Nanoscience and Technology, Beijing   27          489

###### 

Top 10 journals published in the area of nanotechnology and triple negative breast cancer

  Journal                                              Impact factor (2016)   Documents   Citations
  ---------------------------------------------------- ---------------------- ----------- -----------
  *Biomaterials*                                       8.402                  120         4,018
  *International Journal of Nanomedicine*              4.300                  113         1,332
  *International Journal of Pharmaceutics*             3.649                  70          970
  *Journal of Controlled Release*                      7.786                  61          1,198
  *Colloids and Surfaces B Biointerfaces*              3.887                  61          869
  *Molecular Pharmaceutics*                            4.440                  60          1,201
  *Nanomedicine Nanotechnology Biology and Medicine*   5.720                  36          550
  *PLoS One*                                           2.806                  36          370
  *Nanomedicine*                                       4.727                  34          269
  *Journal of Biomedical Nanotechnology*               4.521                  34          322

###### 

Top 10 authors in the area of nanotechnology and triple negative breast cancer

  Author                 Affiliation                                                                                                                                             Documents (total)                                                                                                                                                                                                                        h-Index (total)   Most cited article (total)                                                                                                                                                                                              Citations of the most cited paper   Citations (total) by documents   References
  ---------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------- -------------------------------- --------------------
  Li, Yaping             Shanghai Institute of Materia Medica, Chine Academy of Sciences, State Key Laboratory of Drug Research and Center of Pharmaceutics, Shanghai, China     174                                                                                                                                                                                                                                      44                Li Y-P, et al. PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats. *J Control Release*. 2001;71(2):203--211                                                           336                                 6,439 by 5,004                   [@b21-ijn-13-2321]
  23                     15                                                                                                                                                      Tang S, et al. Co-delivery of doxorubicin and RNA using pH-sensitive poly (β-amino ester) nanoparticles for reversal of multidrug resistance of breast cancer. *Biomaterials*. 2014;35(23):6047--6059                                    56                524 by 490                                                                                                                                                                                                              [@b22-ijn-13-2321]                                                   
  Atyabi, F              Tehran University of Medical Sciences, Nanotechnology Research Centre, Tehran, Iran                                                                     189                                                                                                                                                                                                                                      34                Dinarvand R, et al. Polylatide-co-glycolide nanoparticles for controlled delivery of anticancer agents. *Int J Nanomed*. 2011;6:877--895                                                                                154                                 3,862 by 3,104                   [@b23-ijn-13-2321]
  18                     8                                                                                                                                                       Taheri A, et al. The in vivo antitumor activity of LHRH targeted methotrexate-human serum albumin nanoparticles in 4T1 tumor-bearing Balb/c mice. *Int J Pharm*. 2012;431(1--2):183--189                                                 26                155 by 142                                                                                                                                                                                                              [@b24-ijn-13-2321]                                                   
  Yu, Hainjun            Shanghai Institute of Materia Medica, Chinese Academy of Sciences, State Key Laboratory of Drug Research and Center of Pharmaceutics, Shanghai, China   82                                                                                                                                                                                                                                       24                Duan X, et al. Smart pH-sensitive and temporal-controlled polymeric micelles for effective combination therapy of doxorubicin and disulfiram. *ACS Nano*. 2013;7(7):5858--5869                                          156                                 1,949 by 1,495                   [@b25-ijn-13-2321]
  18                     12                                                                                                                                                      Tang S, et al. Co-delivery of doxorubicin and RNA using pH-sensitive poly (β-amino ester) nanoparticles for reversal of multidrug resistance of breast cancer. *Biomaterials*. 2014;35(23):6047--6059                                    56                437 by 374                                                                                                                                                                                                              [@b22-ijn-13-2321]                                                   
  Zhang, Z               Shanghai Institute of Materia Medica, Chinese Academy of Sciences, State Key Laboratory of Drug Research and Center of Pharmaceutics, Shanghai, China   116                                                                                                                                                                                                                                      31                He Q, et al. In vivo biodistribution and urinary excretion of mesoporous sílica nanoparticles: effects of particle size PEGylation. *Small*. 2011;7(2):271--280                                                         262                                 3,624 by 2,855                   [@b26-ijn-13-2321]
  17                     12                                                                                                                                                      Tang S, et al. Co-delivery of doxorubicin and RNA using pH-sensitive poly (β-amino ester) nanoparticles for reversal of multidrug resistance of breast cancer. *Biomaterials*. 2014;35(23):6047--6059                                    56                431 by 368                                                                                                                                                                                                              [@b22-ijn-13-2321]                                                   
  Yin, Qi                Shanghai Institute of Materia Medica, Chinese Academy of Sciences, State Key Laboratory of Drug Research, Shanghai, China                               69                                                                                                                                                                                                                                       27                Gao Y, et al. Controlled intracellular release of doxorubicin in multidrug-resistant cancer cells by tuning the shell-pore sizes of mesoporous sílica nanoparticles. *ACS Nano*. 2011;5(12):9788--9798                  197                                 2,082 by 1,620                   [@b27-ijn-13-2321]
  16                     10                                                                                                                                                      Tang S, et al. Co-delivery of doxorubicin and RNA using pH-sensitive poly (β-amino ester) nanoparticles for reversal of multidrug resistance of breast cancer. *Biomaterials*. 2014;35(23):6047--6059                                    56                387 by 338                                                                                                                                                                                                              [@b22-ijn-13-2321]                                                   
  Akbarzadeh, Abolfazl   Tabriz University of Medical Sciences, Department of Medical Nanotechnology, Tabriz, Iran                                                               141                                                                                                                                                                                                                                      25                Akbarzadeh A, et al. Liposome: classification preparation, and applications. *Nanoscale Res Lett*. 2013;8(1):1--8                                                                                                       295                                 2,202 by 1,365                   [@b28-ijn-13-2321]
  14                     6                                                                                                                                                       Ghasemali S, et al. Inhibitory effects of β-cyclodextrin-helenalin complexes on H-TERT gene expression in the T47D breast cancer cell line -- results of real time quantitative PCR. *Asian Pac J Cancer Prev*. 2013;14(11):6949--6953   36                115 by 94                                                                                                                                                                                                               [@b29-ijn-13-2321]                                                   
  Wang, Wueqing          Peking University, Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, Beijing, China                                      118                                                                                                                                                                                                                                      27                Dai J, et al. pH-sensitive nanoparticles for improving the oral bioavailability of cyclosporine A. *Int J Pharm*. 2004;280(1--2):229--240                                                                               123                                 2,064 by 1,667                   [@b30-ijn-13-2321]
  14                     8                                                                                                                                                       Wang Z, et al. The use of a tumor metastasis targeting peptide to deliver doxorubicin-containing liposomes to highly metastatic cancer. *Biomaterials*. 2012;33(33):8451--8460                                                           64                271 by 250                                                                                                                                                                                                              [@b31-ijn-13-2321]                                                   
  Zhang, Qiang           Peking University, State Key Laboratory of Natural and Biomimetic Drugs, Beijing, China                                                                 109                                                                                                                                                                                                                                      22                Zhang Y, et al. The eradication of breast cancer and cancer stem cells using octreotide modified paclitaxel active targeting micelles and salinomycin passive targeting micelles. *Biomaterials*. 2012;33(2):679--691   104                                 1,413 by 1,201                   [@b32-ijn-13-2321]
  14                     7                                                                                                                                                       Feng Q, et al. Synergistic inhibition of breast cancer by co-delivery of VEGF siRNA and paclitaxel via vapreotide-modified core-shell nanoparticles. *Biomaterials*. 2014;35(18):5028--5038                                              57                245 by 234                                                                                                                                                                                                              [@b33-ijn-13-2321]                                                   
  Dinarvand, Rassoul     Tehran University of Medical Sciences, Nanotechnology Research Center, Tehran, Iran                                                                     294                                                                                                                                                                                                                                      37                Ganjali MR, et al. Schiff's bases and crown ethers as supramolecular sensing materials in the construction of potentiometric membrane sensors. *Sensors*. 2008;8(3):1645--1703                                          169                                 5,580 by 4,455                   [@b34-ijn-13-2321]
  13                     7                                                                                                                                                       Taheri A, et al. The in vivo antitumor activity of LHRH targeted methotrexate-human serum albumin nanoparticles in 4T1 tumor-bearing Balb/c mice. *Int J Pharm*. 2012;431(1--2):183--189                                                 26                129 by 123                                                                                                                                                                                                              [@b24-ijn-13-2321]                                                   
  Ferrari, Mauro         Methodist Hospital Houston, Department of Nanomedicine, Houston, USA                                                                                    450                                                                                                                                                                                                                                      65                Ferrari M. Cancer nanotechnology: opportunities and challenges. *Nat Rev Cancer*. 2005;5(3):161--171                                                                                                                    2,700                               17,952 by 11,803                 [@b35-ijn-13-2321]
  13                     10                                                                                                                                                      Xu R, et al. Na injectable nanoparticle generator enhances delivery of cancer therapeutics. *Nat Biotechnol*. 2016;34(4):414--418                                                                                                        62                336 by 253                                                                                                                                                                                                              [@b36-ijn-13-2321]                                                   

###### 

Patents filed by the top 10 authors in the area of nanotechnology and triple negative breast cancer

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Inventors                                                                                                                                                                                                                                                                                                                                                                    Patent name                                                                                           Applicant                                                         Date of filing      Patent office                                                                                                                                                           Patent number
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------- ----------------------------------------------------------------- ------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------
  Li, Yaping (Pudong Shanghai, CN); Chen, Lingli (Pudong Shanghai, CN); Zheng, Zhaolei (Pudong Shanghai, CN); Zhang, Zhiwen (Pudong Shanghai, CN); Gu, Wangwen (Pudong Shanghai, CN)                                                                                                                                                                                           Irinotecan hydrochloride composite phospholipid composition, preparation method and use thereof       Shanghai Institute of Materia Medica, Chinese Academy Sciences\   March 6, 2015       United States Patent and Trademark Office Pre-Granted Publication United Kingdom Patent Application United States Patent and Trademark Office Pre-Granted Publication   US20170087146\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Shanghai Jingfeng Pharmaceutical CO., LTDA                                                                                                                                                                                                                    GB20160016625 20150306

  Gillman, Kevin W (Madison, CT); Goodrich, Jason (Wallingford, CT); Boy, Kenneth M (Durham, CT); Zhang, Yunhui (Glastonbury, CT); Mapelli, Claudio (Lawrenceville, NJ); Poss, Michael A (Lawrenceville, NJ); Sun, Li-Qiang (Glastonbury, CT); Zhao, Qian (Wallingford, CT); Mull, Eric (Guilford, CT); Gillis, Eric P (Cheshire, CT); Scola, Paul Michael (Glastonbury, CT)   Immunomodulators                                                                                      Bristol-Myers Squibb Company                                      November 11, 2015   US20160137696                                                                                                                                                           

  Dinarvand, Rassoul (Tehran, IR); Derakhshan, Mohammad Ali (Tehran, IR); Rahbarizadeh, Fatemeh (Tehran, IR); Majidi, Reza Faridi (Tehran, IR); Borujeni, Azade Taheri (Tehran, IR); Rezayat, Seyed Mahdi (Tehran, IR)                                                                                                                                                         Multi-mode cancer targeted nanoparticulate system and a method of synthesizing the same               Dinarvand; Rassoul\                                               January 11, 2012    United States Patent and Trademark Office Pre-Granted Publication                                                                                                       US20130178603
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Derakhshan; Mohammad Ali\                                                                                                                                                                                                                                     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Rahbarizadeh; Fatemeh\                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Majidi; Reza Faridi\                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Borujeni; Azade Taheri\                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Rezayat; Seyed Mahdi                                                                                                                                                                                                                                          

  Mi, Yu (Houston, TX); Ferrari, Mauro (Houston, TX)                                                                                                                                                                                                                                                                                                                           Micro/nano composite drug delivery formulations and uses thereof                                      The Methodist Hospital (Houston, TX, USA)                         August 25, 2016     United States Patent and Trademark Office Pre-Granted Publication                                                                                                       US20170056327

  Shen, Haifa (Houston, TX); Ferrari, Mauro (Houston, TX); Shen, Jian (Houston, TX); Zhang, Mingzhen (Houston, TX)                                                                                                                                                                                                                                                             Polycation-functionalized nanoporous silicon carrier for systemic delivery of gene silencing agents   The Methodist Hospital (Houston, TX, USA)                         December 11, 2015   United States Patent and Trademark Office Pre-Granted Publication                                                                                                       US20160369269

  Ferrari, Mauro (Houston, TX); Tasciotti, Ennio (Houston, TX); Sakamoto, Jason (Houston, TX)                                                                                                                                                                                                                                                                                  Multistage delivery of active agents                                                                  Ferrari; Mauro\                                                   May 29, 2015        United States Patent and Trademark Office Pre-Granted Publication                                                                                                       US20160051481
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Tasciotti; Ennio\                                                                                                                                                                                                                                             
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Sakamoto; Jason                                                                                                                                                                                                                                               
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Clinical trials in the area of nanotechnology and triple negative breast cancer

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study title                                                                                                                                                                                 Status                                                   Interventions                                                                                                         First posted         Sponsors/collaborators                                                     Principal investigators
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------- -------------------- -------------------------------------------------------------------------- -----------------------------
  Carboplatin and paclitaxel albumin-stabilized nanoparticle formulation before surgery in treating patients with locally advanced or inflammatory triple negative breast cancer              Recruiting                                               Drug: carboplatin Drug: paclitaxel albumin-stabilized nanoparticle formulation Other: laboratory biomarker analysis   February 3, 2012     City of Hope Medical Center National Cancer Institute                      Yuan Yuan Stephen C Koehler

  A trial of nanoparticle albumin-bound paclitaxel (nab-paclitaxel, abraxane^®^) with or without mifepristone for advanced, glucocorticoid receptor-positive, triple negative breast cancer   Recruiting                                               Drug: mifepristone\                                                                                                   June 2, 2016         University of Chicago                                                      Rita Nanda\
                                                                                                                                                                                                                                                       Other: placebo\                                                                                                                                                                                                       Gini Fleming
                                                                                                                                                                                                                                                       Drug: nab-paclitaxel                                                                                                                                                                                                  

  Study to evaluate CORT125134 in combination with nab-paclitaxel in patients with solid tumors                                                                                               Recruiting                                               Drug: CORT125134 with nab-paclitaxel                                                                                  May 5, 2016          Corcept Therapeutics                                                       Thaddeus S Block

  Paclitaxel albumin-stabilized nanoparticle formulation and bevacizumab followed by bevacizumab and erlotinib hydrochloride in treating patients with metastatic breast cancer               Active, not recruiting                                   Drug: paclitaxel albumin-stabilized nanoparticle formulation\                                                         August 13, 2008      National Cancer Institute University of Washington                         Jennifer Specht
                                                                                                                                                                                                                                                       Biologic: bevacizumab\                                                                                                                                                                                                
                                                                                                                                                                                                                                                       Drug: erlotinib hydrochloride\                                                                                                                                                                                        
                                                                                                                                                                                                                                                       Other: laboratory biomarker analysis                                                                                                                                                                                  

  Paclitaxel albumin-stabilized nanoparticle formulation in treating older patients with locally advanced or metastatic breast cancer                                                         Active, not recruiting                                   Drug: paclitaxel albumin-stabilized nanoparticle formulation Other: questionnaire administration                      November 1, 2011     National Cancer Institute City of Hope Medical Center                      Arti Hurria

  Veliparib in treating patients with malignant solid tumors that do not respond to previous therapy                                                                                          Active, not recruiting                                   Other: laboratory biomarker analysis\                                                                                 May 4, 2009          National Cancer Institute                                                  Shannon Puhalla
                                                                                                                                                                                                                                                       Other: pharmacologic study\                                                                                                                                                                                           
                                                                                                                                                                                                                                                       Drug: veliparib                                                                                                                                                                                                       

  Neoadjuvant pembrolizumab(Pbr)/Nab-paclitaxel followed by pbr/epirubicin/cyclophosphamide in TNBC                                                                                           Not yet recruiting                                       Drug: pembrolizumab\                                                                                                  September 21, 2017   Merck Sharp & Dohme Corp.\                                                 Peter A Fasching
                                                                                                                                                                                                                                                       Drug: nab-paclitaxel\                                                                                                                      Celgene Corporation\                                                       
                                                                                                                                                                                                                                                       Drug: epirubicin\                                                                                                                          Institut fuer Frauengesundheit                                             
                                                                                                                                                                                                                                                       Drug: cyclophosphamide                                                                                                                                                                                                

  Phase II study with abraxane, bevacizumab and carboplatin in triple negative metastatic breast cancer                                                                                       Completed[\*](#tfn1-ijn-13-2321){ref-type="table-fn"}    Drug: abraxane\                                                                                                       May 28, 2007         Duke University Genentech, Inc.\                                           Kimberly Blackwell
                                                                                                                                                                                                                                                       Drug: bevacizumab\                                                                                                                         Celgene Corporation                                                        
                                                                                                                                                                                                                                                       Drug: carboplatin                                                                                                                                                                                                     

  AZD2281 plus carboplatin to treat breast and ovarian cancer                                                                                                                                 Completed                                                Drug: AZ2281+carboplatin                                                                                              October 3, 2011      National Cancer Institute                                                  Jung-Min Lee

  An efficacy study of trabectedin in the treatment of participants with specific subtypes of metastatic breast cancer                                                                        Completed                                                Drug: dexamethasone Drug: trabectedin                                                                                 December 24, 2007    Johnson & Johnson Pharmaceutical Research and Development, LLC PharmaMar   Not mentioned

  Study of abraxane and carboplatin as first-line treatment for triple negative metastatic breast cancer                                                                                      Terminated[\*](#tfn1-ijn-13-2321){ref-type="table-fn"}   Drug: abraxane Drug: carboplatin                                                                                      September 22, 2010   Duke University\                                                           Kimberly L Blackwell
                                                                                                                                                                                                                                                                                                                                                                                                  Celgene Corporation                                                        
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Note:**

Studies that have results.

###### 

Top 10 cited papers in the area of nanotechnology and triple negative breast cancer

  Authors and journal                                                                                            Article                                                                                                                                       Main results                                                                                                                                                                                     Total citations   Average citations per year   References
  -------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------- ---------------------------- --------------------
  Hrkach J, et al. *Science Translational Medicine*. 2012;4(128):128ra39                                         Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile      Docetaxel encapsulated in polymeric nanoparticle exhibited enhanced tumor accumulation and prolonged tumor growth suppression in low doses also, compared to that typically used in the clinic   445               88.2                         [@b37-ijn-13-2321]
  Ohno S-I, et al. *Molecular Therapy*. 2013;21(1):185--191                                                      Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells                                             Exosomes can efficiently deliver miRNA to EGFR-expressing breast cancer cells, also can be used therapeutically to target EGFR- expressing cancerous tissues with acid drugs                     291               70.5                         [@b38-ijn-13-2321]
  Danhier F, Breton AL, Préat V. *Molecular Pharmaceutics*. 2012;9(11):2961--2973                                RGD-based strategies to target alpha(v) beta (3) integrin in cancer therapy and diagnosis                                                     This review aims to highlight the position of RGD-based nanoparticles in cancer therapy and imaging                                                                                              283               55.4                         [@b39-ijn-13-2321]
  Ge J, et al. *Nature Communications*. 2014;5:4596                                                              A graphene quantum dot photodynamic therapy agent with high singlet oxygen generation                                                         Graphene quantum dots can be used as photodynamic agents allowing imaging and providing a highly efficient cancer therapy                                                                        219               71.7                         [@b40-ijn-13-2321]
  Yuan H, Fales AM, Vo-Dinh T. *Journal of the American Chemical Society*. 2012;134(28):11358--11361             TAT peptide-functionalized gild nanostars: enhanced intracellular delivery and efficient NIR photothermal therapy using ultralow irradiance   The entrance of TAT-peptide-functionalized gold nanostars in the cells is increased after photothermolysis, enhancing its intracellular delivery and action                                      212               41.4                         [@b41-ijn-13-2321]
  Cheng L, et al. *Biomaterials*. 2012;33(7):2215--2222                                                          Multifunctional nanoparticles for upconversion luminescence/MR multimodal imaging and magnetically targeted photothermal therapy              Multifunctional nanoparticles under application of near-infrared laser irradiation promotes photothermal therapeutic efficacy with 100% tumor elimination in in vivo model                       208               41.4                         [@b42-ijn-13-2321]
  King HW, Michael MZ, Gleadle JM. *BMC Cancer*. 2012;12:421                                                     Hypoxic enhancement of exosome release by breast cancer cells                                                                                 Hypoxia promotes the release of exosomes by breast cancer cells mediated by HIF-1α                                                                                                               166               32.4                         [@b43-ijn-13-2321]
  Amoozgar Z, Yeo T. *Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology*. 2012;4(2):219--233   Recent advances in stealth coating of nanoparticle drug delivery systems                                                                      This review aims to disseminate strategies to improve the action of nanoparticles using different synthesis methods and to present general characteristics about it                              156               31.0                         [@b44-ijn-13-2321]
  Pecot CV, et al. *Nature Communications*. 2013;4:2427                                                          Tumour angiogenesis regulation by the miR-200 family                                                                                          miR-200 inhibits angiogenesis in several cancer types through direct and indirect mechanisms by targeting interleukin-8 and CXCl1 secreted by tumor endothelial and cancer cells                 126               31.2                         [@b45-ijn-13-2321]
  She W, et al. *Biomaterials*. 2013;34(9):2252--2264                                                            Dendronized heparin-doxorubicin conjugate-based nanoparticle as pH-responsive drug delivery system for cancer therapy                         The nanoparticles were shown to effectively kill cancer cells in vitro, showed strong antitumor activity, showed high antiangiogenesis effects, and induced apoptosis in vivo                    118               29.0                         [@b46-ijn-13-2321]

**Abbreviation:** HIF, hypoxia-inducible factor.
